Objective
Despite remarkable progress in the management of cardiovascular disease (CVD), major unmet needs remain with regard to mortality, hospitalisations, quality of life (QoL), healthcare expenditures and productivity. Acute coronary syndrome (ACS), atrial fibrillation (AF) and heart failure (HF) are major and growing components of the global CVD burden. Optimal management of these conditions is complicated by their complex aetiology and heterogeneous prognoses. Poor definition at the molecular level and co/multi-morbidities form major challenges for the development and delivery of targeted treatments. This renders response to therapy unpredictable, with large inter-individual variation and, importantly, small or undetectable treatment effects in large trials of unselected patients.
Today’s treatment guidelines still reflect the scientific constraints of an earlier era where clinical markers to guide therapy are limited to conventional risk factors and end-organ damage, and where the main endpoint in clinical trials is patient death. Hence, drug development pipelines from early target validation through to late post-marketing work have proven to be slow, expensive and high-risk: the chance of eventual approval for a CVD drug candidate in Phase I trials is 7%, the lowest of any disease category (shared with oncology) 2. Moreover, tolerability of medication and adherence to treatment show wide variations. There is thus a need for better definition of these diseases, their markers and endpoints (including better segmentation of current heterogeneous patient groups acknowledging underlying mechanisms and comorbidities) and of their outcomes/prognoses (including functional capacity and quality of life [QoL]).
BigData@Heart’s ultimate goal is to develop a Big Data--driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesdata sciencebig data
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencespersonalized medicine
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
3584 CX Utrecht
Netherlands
See on map
Participants (21)
10117 Berlin
See on map
06903 Biot Sophia Antipolis
See on map
1000 Bruxelles / Brussel
See on map
WC1E 6BT London
See on map
CB2 1TN Cambridge
See on map
02215 Cambridge Ma
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
W12 8EU LONDON
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
46010 Valencia
See on map
17177 Stockholm
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
104 22 Stockholm
See on map
20251 Hamburg
See on map
3521 AL Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
B15 2TT Birmingham
See on map
Participation ended
751 05 Uppsala
See on map
51373 Leverkusen
See on map
4056 Basel
See on map
92284 Courbevoie
See on map
80301 Boulder Colorado
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
9014 St Gallen
See on map
3511 MJ Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
751 25 Uppsala
See on map